¡Ya estamos en ! Descubre más

10x Genomics

TXG

Capitalización de mercado USD 9102 M

69.86 USD

-2.53

3.49%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

69.46

-0.40

0.57%

1 día

-3.49%

5 días

-11.77%

1 mes

-3.88%

3 meses

57.06%

6 meses

176.78%

En lo que va del año

320.34%

1 año

464.3%

5 años

-54.66%

10 años

32.44%

Acerca de: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Empleados: 1,178

Atención médica Dispositivos médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 34.8%

Neutral 56.5%

Negativo 8.7%

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026.

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

The Motley Fool

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?

Moderna's stock has skyrocketed on exciting results from its personalized cancer vaccine. Twist Bioscience's synthetic DNA is enjoying strong demand.

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?

Zacks Investment Research

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

Zacks Investment Research

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcher PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced Sentira, a new cloud analysis platform that extends the 10x experience from data generation to experimental conclusions, beginning with Sentira Spatial Analysis.

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

Extraordinary early global demand, ambitious new research programs and an expansive technology roadmap mark the beginning of a new era for biological understanding PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the first commercial shipments of Atera, marking a major milestone for a platform that will redefine what's possible in spatial biology.

10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

3 Analysts, 3 Trades to Make Today

Louis says buy the AI dip

3 Analysts, 3 Trades to Make Today

Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.

Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

Zacks Investment Research

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™